Maximal Androgen Depletion with Abiraterone Acetate (Aa) Followed By Randomization of Maximal Androgen Ablation with Molecular Targeted Therapies Dasatinib or Sunitinib Malate in Metastatic Castrate Resistant Prostate Cancer (Mcrpc). Report on Candidate Predictive Androgen Signaling Signature

Maximal Androgen Depletion with Abiraterone Acetate (Aa) Followed By Randomization of Maximal Androgen Ablation with Molecular Targeted Therapies Dasatinib or Sunitinib Malate in Metastatic Castrate Resistant Prostate Cancer (Mcrpc). Report on Candidate Predictive Androgen Signaling Signature

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2014-09, Vol.25, p.v1
Hauptverfasser: Efstathiou, E., Li Ning Tapia, E., Aparicio, A., Tu, S.M., Wen, S., Hoang, A., Pagliaro, L., Harmon, C., Troncoso, P., Araujo, J.C., Logothetis, C.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:0923-7534
DOI:10.1093/annonc/mdu438.21